

MNKD Products & Pipeline

Cardiometabolic

Orphan Lung

Product	Targeted Indications	Pre-IND	Phase 1	Phase 2	Phase 3	Approval
Afrezza® (insulin human) Inhalation Powder	T1DM / T2DM (adults)					Marketed
	T1DM / T2DM (pediatrics)	PDUFA: Q2 2026				
V-Go® All-in-One Insulin Delivery Patch	T1DM / T2DM (adults)					Marketed
FUROSCIX® (furosemide injection) <small>(marketed by scPharmaceuticals, a wholly owned subsidiary of MannKind)</small>	Edema from CHF / CKD (adults)	Marketed (adults); Pediatrics (PDUFA: Q4 2025)				
FUROSCIX ReadyFlow™ Autoinjector	Edema from CHF / CKD	Submitted sNDA: Q3 2025				
Bumetanide DPI <small>(MNKD-701)</small>	Edema from CHF / CKD	Pre-Clinical				
Tyvaso DPI® (treprostinil) Inhalation Powder <small>(marketed by United Therapeutics)</small>	PAH / PH-ILD					Marketed
Nintedanib DPI <small>(MNKD-201)</small>	IPF	Phase 2 (Inflo-2 study)				
Clofazimine DPI <small>(MNKD-102)</small>	NTM	Pre-Clinical				
Partner Program with United Therapeutics <small>(MNKD-1501)</small>	UNDISCLOSED	STAGE UNDISCLOSED				